patent/ME-00055-B

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2901e694724c2a759f619944cb7d2a4
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
filingDate	2003-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a31940a65465f448a616562505aa696f
publicationDate	2010-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	ME-00055-B
titleOfInvention	Administration of docetaxel / doxorubicin / cyclophosphamide in adjuvant therapy for breast and ovarian cancer
abstract	The present invention relates to a new method of adjuvant therapy in the treatment of metastatic breast or ovarian cancer, comprising administering six cycles of docetaxel, doxorubicin and cyclophosphamide to a diseased patient, the doses having a indicated therapeutic effect compared to other tadjuvant therapies.
priorityDate	2002-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492617 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535314 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124

Total number of triples: 23.